Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

BACKGROUND: EXTEND (NCT01797965), an open-label extension study, evaluated the safety and efficacy of daclizumab beta in participants with relapsing multiple sclerosis (MS) who had completed the randomized DECIDE study. METHODS: Eligible participants who received either daclizumab beta or interferon...

Descripción completa

Detalles Bibliográficos
Autores principales: Kappos, Ludwig, Cohan, Stanley, Arnold, Douglas L., Robinson, Randy R., Holman, Joan, Fam, Sami, Parks, Becky, Xiao, Shan, Castro-Borrero, Wanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934044/
https://www.ncbi.nlm.nih.gov/pubmed/33737954
http://dx.doi.org/10.1177/1756286420987941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934044/
https://www.ncbi.nlm.nih.gov/pubmed/33737954
http://dx.doi.org/10.1177/1756286420987941

Ejemplares similares